Rational Pharmacotherapy in Cardiology

Advanced search

Drug Therapy Structure and Clinical Characteristics of Patients with Atrial Fibrillation According to Data of REKUR-AF Study

Full Text:


Aim. In the framework of the database of patients with atrial fibrillation established in the Kursk region, to study the clinical and anamnestic indicators, the structure of the combined and concomitant diseases in the patients under study, and also to evaluate the usefulness of the diagnostic methods of the study and drug therapy of this pathology.

Material and methods. The regional study (REKUR-AF) included patients with atrial fibrillation (AF) from 18 years of age and older living in the city of Kursk and seven districts of the Kursk region. Recruitment of patients to the study was conducted from September 2015 to August 2016. When analyzing the outpatient charts of the studied patients, demographic data, the type and duration of AF, cardiovascular diseases (CVD), concomitant noncardiac pathology, laboratory and instrumental examination data, information about hospitalizations for the last year, pharmacotherapy were recorded.

Results. The research included 896 patients with AF. Mean  age  of patients was  69  (62-77) years,  women were  significantly older than  men (p<0.001). When analyzing the most common CVD in patients with AF (chronic heart failure, stable exertional angina, arterial hypertension), it was found  that  comorbid pathology was found  in 99.3% of patients. 22.7% of patients had myocardial infarction (MI) in the past,  12.3% – acute  cerebrovascular accident. From concomitant noncardiac diseases, patients with AF most  often  suffered  from chronic kidney disease, obesity, type 2 diabetes, diseases of the gastrointestinal tract. On the average, one patient had 4 (3-4) diagnoses of CVD, and together with concomitant pathology – 5 (4-6). The medical examination was not in line with required level in the existing diseases. The high risk according to CHA2DS2-VASc scale was revealed in 96.3% of patients and according to HAS-BLED scale – in 52.8%. Patients with AF most often  received antiplatelet agents, angiotensinconverting enzyme  inhibitors, β-blockers, statins and  diuretics. Anticoagulants were  only used  in 18.3% of patients. The average number of prescriptions of drugs  in all patients with AF was  5 (4-6) and  was  significantly (p<0.001) higher in the  group  of patients with MI in the  past (6 [4-6]) compared with the cohort of patients without MI (5 [4-6]).

Conclusion. Patients included into the REKUR-AF study were characterized by a high incidence of combined cardiovascular pathology, a high risk of thromboembolic complications. In most patients, anti-platelet drugs were used as antithrombotic therapy, although they are significantly inferior to anticoagulants in their ability to prevent thromboembolic complications. Anticoagulants were used only in every fifth patient, warfarin was a significant part  (52.6%) among all anticoagulants. Patients with AF also had  an insufficient frequency of laboratory and  instrumental examinations, that  is required according to current  guidelines.


About the Authors

I. L. Polshakova
Kursk State Medical University
Russian Federation

Inna L. Polshakova – MD, Post-Graduate Student, Chair of Clinical Pharmacology.

K. Marx ul. 3, Kursk, 305041.


S. V. Povetkin
Kursk State Medical University
Russian Federation

Sergey V. Povetkin – MD, PhD, Professor, Head of Chair of Clinical Pharmacology.

K. Marx ul. 3, Kursk, 305041.



1. Sulimov V.A., Golitsyn S.P., Panchenko E.P. et al. Diagnostics and treatment of atrial fibrillation. Recommendations of RSC, RSSA and ACVS. Russian Journal of Cardiology 2013;(4):1-100. (In Russ.). doi:10.15829/1560-4071-2013-4s3.

2. Diagnosis and treatment of atrial fibrillation. Recommendations of RSC/RSSA/ACVS (2017). [cited by Oct 10, 2018]. Available from: (In Russ.).

3. The general incidence of all population of Russia in 2016. Statistical materials (Part II). Moscow: Federal research institute for health organization and informatics of ministry of health of the Russian federation; 2017. (In Russ.).

4. The general incidence of all population of Russia in 2014. Statistical materials (Part II). Moscow: Federal research institute for health organization and informatics of ministry of health of the Russian federation; 2015. (In Russ.).

5. Loukianov M.M., Boytsov S.A., Yakushin S.S. et al. Diagnostics, treatment, associated cardiovascular and concomitant non-cardiac diseases in patients with diagnosis of "atrial fibrillation" in real outpatient practice (according to data of Registry of CardioVAscular Diseases RECVASA). Rational Pharmacotherapy in Cardiology. 2014;10(4):366-78. (In Russ.). doi:10.20996/1819-6446-2014-10-4-366-377.

6. Belousov D.U. Non-interventional studies. Good Clinical Practice. 2017;1:24-33. (In Russ.).

7. Erlikh A.D., Tkachenkо K.G., Utyomov A.A. et al. The Use of Oral Anticoagulants in Patients with Acute Coronary Syndrome and Atrial Fibrillation in Clinical Practice (RECORD Register). Lechebnoe Delo. 2017;1:51-6. (In Russ.).

8. Korennova O.Yu., Mal'tcev S.N., Petrenko A.V., Bulakhova E.Yu. Atrial fibrillation in real clinical practice: lessons of one regional register. Difficult Patient. 2015;13(4):8-11. (In Russ.).

9. Martsevich S.Yu., Kutishenko N.P., Suvorov A.Yu. et al. Characteristics of patients with cerebral stroke or transient ischemic attack, included into the LIS-2 register (Lyubertsy study of mortality in patients after stroke). Rational Pharmacotherapy in Cardiology. 2015;11(1):18-24. (In Russ.). doi:10.20996/1819-6446-2015-11-1-18-24.

10. Martsevich S.Y., Navasardyan A.R., Kutishenko N.P., et al. Workgroup Studying atrial fibrillation on the basis of the “PRoFILE” registry. Cardiovascular Therapy and Prevention. 2014;13(2):35-9. (In Russ.).

11. Mikhin V.P., Maslennikova Yu.V., Loukianov M.M. Patients with atrial fibrillation and ishemic heart disease: hospitalization structure and antitrombotic therapy (RECVASA AF-KURSK registry). Arhiv Vnutrennej Mediciny 2017;7(3):217-23. (In Russ.). doi:10.20514/2226-6704-2017-7-3-217-223.

12. Shlyakhto E.V., Ezhov A.V., Zenin S.A. et al. Clinical portrait of the atrial fibrillation patient in Russian Federation. Data from the global registry GLORIA AF. Russian Journal of Cardiology. 2017;9(149):21-7. (In Russ.). doi:10.15829/1560-4071-2017-9-138-142.

13. Stepina E.V., Loukianov M.M., Bichurina M.A. et al. The structure of the cardiovascular diseases and drug treatment in patients with combination of atrial fibrillation, arterial hypertension, ischemic heart disease, chronic heart failure: RECVASA-CLINICA registry data. Preventive Medicine. 2016;19(2):73-4. (In Russ.).

14. Tereshchenko S.N., Zhirov I.V., Romanova N.V. et al. The first Russian register of patients with chronic heart failure and atrial fibrillation (RIF-CHF): study design. Rational Pharmacotherapy in Cardiology. 2015;11(6):577-81. (In Russ.). doi:10.20996/1819-6446-2015-11-6-577-581.

15. Valiakhmetov M. N., Gomova T. A., Loukianov M. M. et al. Patients with Atrial Fibrillation in Multidisciplinary Hospital: Structure of Hospitalization, Concomitant Cardiovascular Diseases and Drug Treatment (Data of RECVASA AF-Tula Registry). Rational Pharmacotherapy in Cardiology. 2017;13(4):495-505. (In Russ.). doi:10.20996/1819-6446-2017-13-4-495-505.

16. Zolotovskaya I.A., Davydkin I.L., Duplyakov D.V. Newly diagnosed stroke-associated atrial fibrillation^risk of development of unfavorable clinical outcomes (The results of the subanalysis cohort study APOLLO). Arhiv Vnutrennej Mediciny. 2017;7(5):364-70. (In Russ.). doi:10.20514/2226-6704-2017-7-5-364-370.

17. Yakusevich V.V., Pozdnyakova E.M., Yakusevich Vl.V. et al. An outpatient with atrial fibrillation: key features. The first data of REKVAZA FP - YAROSLAVL register. Rational Pharmacotherapy in Cardiology. 2015;11(2):149-52. (In Russ.). doi:10.20996/1819-6446-2015-11-2-149-152.

18. Borovikov V.P., Borovikov I.P. Statistica. Statistical analysis and data processing in a Windows. Moscow: Filin; 1998. (In Russ.).

19. Glantz S. Medico-biological statistics. Moscow: Practice; 1999. (In Russ.).

20. Mikhin V.P., Maslennikova Yu.V., Lukyanov M.M. Kudryashov E.V. Drug therapy in patients with coronary heart disease in combination with atrial fibrillation in real medical practice (results of RECVASA AF-Kursk registry). Kursk Scientific and Practical Bulletin "Man and His Health". 2017;2;49-54. (In Russ.) doi:10.21626/vestnik/2017-2/09.

21. Stepina E.V., Lukyanov M.M., Bichurina M.A. et a l. Prescription of medications influencing prognosis in atrial fibrillation with arterial hypertension, coronary heart disease, chronic heart failure, by the registry REKVAZA-CLINIC. Cardiovascular Therapy and Prevention. 2017;16(2):33-8. (In Russ.). doi:10.15829/1728-8800-2017-2-33-38.

22. Loukianov M.M., Martsevich S.Yu., Yakushin S.S. et al. The Control of International Normalised Ratio in Patients with Atrial Fibrillation Treated with Warfarin in Outpatient and Hospital Settings: Data from RECVASA Registries. Rational Pharmacotherapy in Cardiology. 2018;14(1):40-6. (In Russ.). doi:10.20996/1819-6446-2018-14-1-40-46.

23. Petrov V.I., Shatalova O.V., Maslakov A.S. Analysis of antitrombotic therapy in in-patients with permanent atrial fibrillation (pharmacoepidemiology study). Rational Pharmacotherapy in Cardiology. 2014;10(2):174-8. (In Russ.). doi:10.20996/1819-6446-2014-10-2-174-178.

24. Akhmedzhanov N.M., Nebieridze D.V., Safaryan A.S. et al. Lipid-lowering therapy in outpatient practice (according to the ARGO-2 study). Rational Pharmacotherapy in Cardiology. 2016;12(2):147-53. (In Russ.) . doi:10.20996/1819-6446-2016-12-2-147-153.

For citation:

Polshakova I.L., Povetkin S.V. Drug Therapy Structure and Clinical Characteristics of Patients with Atrial Fibrillation According to Data of REKUR-AF Study. Rational Pharmacotherapy in Cardiology. 2018;14(5):733-740. (In Russ.)

Views: 457

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)